This project is funded by the EU's #Horizon2020 program under grant agreement No 754803. Any related tweets reflect only the views of the project owner.
💥News from LBCT - Session 1
🔍The CONVINCE Trial, published in the New England Journal of Medicine, indicate that the wider use of high dose HDF would have clear benefits for patients living with end-stage chronic kidney disease (CKD).
Read more 👉 https://t.co/6aeC8YEWaf
CONVINCE trial results show that high dose haemodiafiltration reduces mortality of kidney dialysis patients. The results of the CONVINCE trial were presented today at the ERA meeting in Milan
https://t.co/MqkWuQKKPk
and published in the NEJM https://t.co/6hOdvmUHFt
The primary results of the CONVINCE trial will be presented on Friday 16th June 2023 at 12:00 - 13:15 CET in the Late Breaking Trials session at the ERA Meeting in Milan https://t.co/WMC0WpvsLi
Abstract presented at the 29th Annual Conference ISOQOL 2022 in Prague has been published in Quality of Life Research (2022) Vol 31 (Suppl 2): S22. https://t.co/vJypK9WVVD (102.2)
Our results indicate that the effects of haemodiafiltration on survival can be predicted using a combination of readily available patient and disease characteristics, which could guide shared decision-making.
2/2
The paper “Personalizing treatment in end-stage kidney disease: deciding between haemodiafiltration and haemodialysis based on individualized treatment effect prediction” is now published in Clinical Kidney Journal https://t.co/IzEHs9HCfk
1/2
Congratulations to Robin Vernooij @robinvernooij whose contribution was selected as one of the best abstracts presented by young authors at the 58th ERA-EDTA Congress in Berlin in June 2021. @ERAEDTA
https://t.co/QuuvfV5jUt
Recruitment for CONVINCE has ended - 1360 patients have been enrolled in the study. For the latest recruitment images, please see https://t.co/p595RPWeHH
We have 2 weeks to go until the end of the recruitment phase. Our adjusted target was 1200 patients, but we have passed the 1300 mark! This is great news! From April we can start working on the baseline data.
A recent interview with CONVINCE team at Charité re patient reported outcomes.
https://t.co/ITdTlF95Oh
For a full version of this interview, please visit the CONVINCE website https://t.co/y8kLyQ8lvO
@DiaverumGlobal@ChariteBerlin@JuliusClinical @FMC_AG
A recent interview with CONVINCE team at Charité re patient reported outcomes.
https://t.co/ITdTlF95Oh
For a full version of this interview, please visit the CONVINCE website https://t.co/y8kLyQ8lvO
@EKHA_EU @bbraun_de @ERAEDTA@ASNKidney@kidneycareuk